Issue and re-purchase of class C shares for shareholder program

Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares.

The shares are issued and re-purchased in accordance with the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024, which were adopted by the Annual General Meetings 2022 and 2024, respectively, as well as other outstanding shareholder programs for members of the Board of Directors (the “Incentive Programs”).

DNB Bank ASA, Sweden Branch will subscribe for the entire issue of new class C shares at a subscription price of approximately SEK 0.11 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the Board of Directors’ resolution, be re-purchased by DNB Bank ASA, Sweden Branch for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of the Incentive Programs.

The purpose of the re-purchase is to ensure delivery of shares in accordance with the Incentive Programs as well as to cover any social costs due to Co-worker LTIP 2022 and Co-worker LTIP 2024. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.